Low cdc27 and high securin expression predict short survival for breast cancer patients
Article first published online: 12 JUN 2013
© 2013 APMIS. Published by John Wiley & Sons Ltd
Volume 121, Issue 10, pages 945–953, October 2013
How to Cite
Low cdc27 and high securin expression predict short survival for breast cancer patients. APMIS 2013; 121: 945–953., , , , , , , , .
- Issue published online: 20 SEP 2013
- Article first published online: 12 JUN 2013
- Manuscript Accepted: 15 MAR 2013
- Manuscript Received: 5 OCT 2012
- Turku University Central Hospital
- Cancer Society of South-Western Finland
- cell cycle;
- breast cancer;
Cell cycle regulators cdc27 and securin participate in control of the mitotic checkpoint and survey the mitotic spindle to maintain chromosomal integrity. This is achieved by their functions in metaphase–anaphase transition, DNA damage repair, enhancement of mitotic arrest and apoptosis. We report on the roles of cdc27 and securin in aneuploidy and prognosis of breast cancer. The study comprises 429 breast cancer patients with up to 22 years of follow-up. DNA content was determined by image cytometry, and immunopositivity for cdc27 and securin was based on tissue microarrays. An inverse association between cdc27 and securin expression was observed in both image cytometric and immunohistochemical analyses. Low cdc27 and high securin expression identified patients with significant difference in disease outcome. Cdc27 and securin immunoexpression identified patients at risk of early cancer death within five years from diagnosis. In multivariate analysis, the combination of cdc27 and securin immunohistochemistry was the strongest predictor of cancer death after lymph node status. We demonstrate, for the first time in human breast cancer, the prognostic value of cdc27 and securin immunohistochemistry. Cdc27 and securin appear promising biomarkers for applications in predicting disease progression, prognostication of individual patients and potential in anti-mitotic drug development.